LYON, France--(BUSINESS WIRE)--Regulatory News:
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP; OTC US - EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces that an independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the company’s Expanded Access Program (EAP) in Acute Lymphoblastic Leukemia (ALL) and recommended continuation of the program without modification.
Help employers find you! Check out all the jobs and post your resume.
